|By Business Wire||
|May 30, 2014 02:08 PM EDT||
In 15 sessions, GfK’s Health division will explore key issues impacting health providers’ product lifecycle strategies – as well as patients’ ability and willingness to pay for improved health – at this week’s International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference in Montreal.
Echoing the conference theme, “Examining the Role of Big Data in Health Care Decision Making,” GfK will highlight findings from its Market Access professionals and its Roper Diabetes and Disease Atlas offerings to shed light on quality of life and socio-economic factors that play a key role in stakeholder decision making.
For a full listing of GfK’s presentations, click here.
“Health care manufacturers and payers require integrated insights from comprehensive data sources to find the smartest paths to improved return on investment – whether that is measured in patient satisfaction, health outcomes or corporate bottom lines,” said David Mackenzie, global lead for GfK’s Health division. “Evidence-based research and real-world findings culled from ‘Big Data’ are key to sound strategy and successful products and services. GfK’s diverse presentations at the ISPOR conference illuminate the medical industry’s need for a continued focus on accuracy as well as an openness to new insight sources.”
Overall, 20 members of GfK’s Health team, representing GfK’s global network, will be attending the ISPOR conference. GfK professionals will be at Booth 14 at the Palais de Congrès de Montréal, May 31 through June 4, 2014.
At ISPOR, GfK podium / panel presentations will include:
- “Assessing Whether ‘Big Data’ Solutions Provide Value for Molecular Diagnostic Manufacturers.” The high cost of purchasing data hinders a majority of molecular diagnostic companies, and existing, incomplete data sets do not allow for informed decision making. GfK’s Susan Garfield (US Co-Lead, Market Access, Health) will discuss how bringing together disparate data sources and improving the coding system for molecular diagnostics and electronic medical records (EMRs) will enable more granular, cost-effective analyses of diagnostic impact.
- “EQ5D – Which Dimension Matters Most Among Diabetes Patients?” GfK’s Koenraad Dierick (Health Economics and Outcomes Research Director, Disease Atlas, Health) will provide details from a GfK Roper Global Diabetes Program study that captured information from 1,480 US diabetes patients on Health-Related Quality of Life (HRQoL). Using EQ-5D, the study revisited the main factors that negatively influence HRQoL scores of diabetes patients.
- “Risk Sharing for Medical Devices: Has the Time Come?” GfK’s Susan Garfield will moderate this panel session.
- “How Variation in HTA Processes and Requirements for Molecular Diagnostics Creates Challenges for Manufacturer, Payer and Clinical Stakeholders.” GfK's Susan Garfield will act as moderator for this ISPOR Forum session.
GfK’s Market Access professionals partner with health care companies seeking expert support in pricing, reimbursement, health economics and market access, providing critical insight and knowledge of local health care systems in current and emerging markets.
GfK Disease Atlas comprises global, prospective, cross-section surveys of real-world practice and its impact on patients, with combined insights from physicians, patients and payers that provide essential context to the decisions driving health care provision.
The Roper Global Diabetes Program provides the definitive global perspective on diabetes. Based on feedback from diagnosed patients, the studies provide key information on every facet of diabetes – from patient attitudes and demographics, to product awareness and usage, to source of care and insurance / reimbursement.
Established in 1995, ISPOR promotes the science of pharmacoeconomics (health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being, including clinical, economic and patient-centered outcomes) and facilitates the translation of this research into useful information for health care decision makers to increase the efficiency, effectiveness, and fairness of health care to improve health.
GfK is the trusted source of relevant market and consumer information that enables its clients to make smarter decisions. More than 13,000 market research experts combine their passion with GfK’s 80 years of data science experience. This allows GfK to deliver vital global insights matched with local market intelligence from more than 100 countries. By using innovative technologies and data sciences, GfK turns big data into smart data, enabling its clients to improve their competitive edge and enrich consumers’ experiences and choices.